Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO®) in Renal Cell Carcinoma Patients With Bone Metastases.

NCT02880943 is registered in ClinicalTrials.gov with Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie as lead sponsor.

NCT NCT02880943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02880943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO®) in Renal Cell Carcinoma Patients With Bone Metastases.
Lead sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
February 28, 2021
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, clear-cell metastatic renal cell carcinoma